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Introduction: Prompt diagnosis of candidaemia and invasive candidosis is crucial to the early initiation of
antifungal therapy. The poor sensitivity of blood cultures (BCs) has led to the development of fungal glycan tests as
a diagnostic adjunct. We analysed the performance of tests for the detection of circulating β-D-1,3-glucan (BDG)
and mannan in the intensive care unit (ICU) setting.
Methods: This retrospective, case–control study included 43 ICU patients with candidaemia and 67 controls,
hospitalised on the same ward and assessed weekly for yeast colonisation with simultaneous serum sampling;
340 sera taken before and after positive BCs were available for the cases group and 203 for the controls. BDG and
mannan levels were determined using the Fungitell® and Platelia™ Candida Ag tests, respectively.
Results: BDG was detected early in sera from cases patients but was also present in several sera from controls.
Increasing the cut-off from 80 pg/mL to 350 pg/mL and 800 pg/mL resulted in sensitivity/specificity ratios of
0.97/0.31, 0.65/0.74, 0.30/0.86, respectively. Detection of mannan was more specific but lacked sensitivity. No
obvious correlation was found between BDG and colonisation, but a trend existed between high colonisation and
high BDG. Candidaemia relapses were associated with a rise in BDG and mannan but, in contrast to the transient
nature of mannan, BDG persisted up to 7 weeks after positive BCs.
Conclusion: A combination of mannan and BDG tests could be used to guide pre-emptive therapeutic decisions in
ICU patients.Introduction
Invasive candidosis (IC) is one of the leading causes of
nosocomial infection and Candida species rank fourth
among the pathogens involved in bloodstream infections
[1]. Despite current progress in research and antifungal
therapy, the incidence and attributable mortality of
candidaemia remain high [2] due to difficulties in the
establishment of an accurate and early diagnosis. In the
ICU, candidaemia has a prevalence of 7/1,000 patients,* Correspondence: dpoulain@univ-lille2.fr
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unless otherwise stated.with an attributable mortality of >40% compared with
30% for bacteraemia [3]. Mortality increases from 10% if
antifungal therapy is introduced within 12 hours of the
onset of candidaemia to 35% when treatment is initiated
more than 48 hours after [4]. These figures are worse in
cases of septic shock due to Candida species [5]. The
challenge is therefore to manage the delay in initiation
of antifungal treatment, especially as 50% of cases of IC
are not detected by blood cultures (BCs) and 48 hours
are generally required for yeast isolation [6]. This low sen-
sitivity of BCs was observed in several large postmortem
studies evaluating the sensitivity of BCs for the diagnosis
of deep-seated Candida invasion [7] and was shown to
range from 28% in cases of single organ candidosis to 58%td. This is an Open Access article distributed under the terms of the Creative
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tems has only decreased the delay in yeast isolation for
certain species without any improvement in the sensitivity
[9]. Relying on BCs or waiting for BC results is thus not
appropriate for managing patients at high risk of IC.
Considering the need for alternatives to BCs for early
diagnosis, the Infectious Diseases Society of America
and the European Society of Clinical and Microbiology
and Infectious Diseases have recommended the use of
nonculture-based methods to help make therapeutic
decisions [10,11]. Among the surrogate markers, some
Candida cell-wall-derived polysaccharides or oligosac-
charides resulting from their catabolism (glycans) can
be detected in the sera of patients with candidosis. These
consist of mannan, a polymer of mannose representing
the polysaccharide moiety of molecules from the outer cell
wall layers, and β-D-1,3-glucan (BDG), a polymer of
glucose making up the fibrils in the middle layers. The
combined detection of glycan biomarkers and anti-
mannan antibodies was also recommended in the last
Surviving Sepsis Campaign for documentation of the
microorganisms involved in septic shock [12]. Numerous
studies have evaluated mannan and BDG detection tests
for the diagnosis of IC in patients with haematological
malignancies and in surgical ICU patients; however,
information about the value of glucanaemia and manna-
naemia monitoring is scarce.
In this study, we looked at ICU patients with candi-
daemia and control patients from the same ward and
with the same high-risk factors/predisposing conditions
for IC with the aim of analysing BDG and mannan levels
during hospitalisation in relation to candidaemia onset
or Candida colonisation. The primary evaluation mea-
sure was an assessment of the two tests to make an early
diagnosis of candidaemia. In addition, we analysed how
these biomarkers could predict candidaemia relapses or
a favourable outcome. Finally, we propose a biomarker-
based algorithm designed especially for the management
of ICU patients, most of whom are at high risk of IC.
Materials and methods
Patients
This retrospective, case–control study involved adult
patients hospitalised in a 50-bed polyvalent ICU depart-
ment in a tertiary university teaching hospital. The data-
base of the clinical mycology laboratory was screened to
select patients with a positive BC for Candida over the
period 2005 to 2010. We focused on patients >18 years
old for whom sera were available at least 1 week before
and 1 week after the day of candidaemia. The control
group consisted of patients hospitalised on the same ward
with Candida colonisation but no evidence of IC; five
body sites (urine, anal swabs, nasal swabs, throat and
tracheal aspirates when patients were intubated) weresampled once a week for the semi-quantitative determin-
ation of yeast colonisation. The medical files for these pa-
tients were analysed retrospectively using a standardised
questionnaire to look for arguments for IC based on the
criteria previously used by Mohr and colleagues [13] and
derived from the European Organisation for Research and
Treatment of Cancer/Mycoses Study Group criteria [14].
We also looked for evidence of invasive aspergillosis and in-
fection by Pneumocystis jirovecii and excluded patients who
had criteria for these two opportunistic fungal infections.
Blood cultures
BCs were performed by drawing 10 ml blood from either
the peripheral vein or arterial catheters into Mycosis ICF
vials incubated at 37°C for up to 7 days in a Bactec FX
System (Becton Dickinson, Le Pont de Claix, France).
Measurement of β-D-1,3-glucan in serum
BDG in serum was measured using the Fungitell® kit (Asso-
ciates of Cape Cod Inc., Falmouth, MA, USA), following the
manufacturer’s instructions. The recommended cutoff value
of 80 pg/ml was used to define positivity. Samples with BDG
levels >500 pg/ml were diluted and retested.
Measurement of mannan antigen and anti-mannan antibodies
in serum
Mannan antigen and anti-mannan antibodies were measured
using the Platelia™ Candida Ag (mannan) and Platelia™
Candida Ab (mannan Ab) tests (Bio-Rad, Marnes la Coquette,
France) according to the manufacturer’s instructions. The
recommended cutoff values for the mannan and mannan Ab
tests used between 2005 and 2010 were 0.5 ng/ml and
>10 AU, respectively. Samples with mannan >500 pg/ml were
diluted and retested.
Intensity of colonisation
Colonisation intensity was determined for each date of
sampling in the control group. Each sample was incu-
bated on Chromagar® (Becton Dickinson, Heidelberg,
Germany) medium under standard conditions. Presump-
tive identification was confirmed by ad hoc tests
(Bichrolatex and glabrata RTT, Fumouze Diagnostics,
Levallois-Perret, France; API 20C, Biomérieux France,
Craponne) and the number of colony-forming units was
scored as follows: score 1, <10 colony-forming units;
score 2, 10 to 50 colony-forming units; score 3, >50
colony-forming units; score 4, >50 colony-forming units
confluent. Intensity of colonisation was determined for
each date of sampling, by dividing the sum score for
each colonised site by the number of sites sampled
giving a mean Candida load. An overall score of >4 was
possible in the case of isolation of several Candida spe-
cies because we added together the colonisation inten-
sity for each species.
Table 1 Major characteristics of patients
Characteristic Cases Controls P value






Sex ratio (male/female) 2.9 2.3 0.67
Simplify Acute Physiology Score 51.5 53.0 0.23
Surgical patient 37.2 20.3 0.07
Abdominal surgery 30.2 10.5 0.01
Other surgery 7.0 10.5 0.7




Corticoids 30.2 39.7 0.41
Vasopressor therapy 65.1 57.8 0.55
Exclusive parenteral nutrition 37.2 4.7 <5 × 10−5











Neutropaenia 7.0 6.4 1




Liposomal amphotericin-B 5.4 9.1
5-Fluorocytosine 2.7 0














ICU mortality 62.8 38.5 0.02
Hospital mortality 65.1 44.6 0.05
Quantitative data are expressed as mean (25th to 75th quartile). Qualitative
data are expressed as a percentage.
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were derived from a systematic weekly survey of urine,
nasal, tracheal and anal colonisation for the isolation of
multiresistant bacteria, where yeasts were also isolated.
Statistical analysis
Quantitative variables are expressed as median values and
95% confidence intervals. Qualitative variables were analysed
using Fisher’s exact test and quantitative variables using the
Wilcoxon test. Tests were two-tailed. Pearson’s correlation
test was performed when necessary. A significance threshold
of 0.05 was retained. All statistical analyses were performed
using EpiInfo V3.5.3 (Centers for Disease Control and
Prevention). Graphics were drawn using Graphpad Prism6
(GraphPad Software, San Diego, California).
Ethical statement
All sera used in this study were sampled from patients
followed in Lille University Hospital. When no results
were available from routine tests, BDG and mannan levels
were determined retrospectively from the residual frozen
samples. No additional sampling was necessary. As sera
were taken from a registered biological collection, patient
consent was not required according to French law. Institu-
tional review board approval was given by the Comité de
Protection des Personnes Nord-Ouest IV, the ethical
committee of our institution.
Results
Description of the study population
A total of 117 patients with candidaemia were identified
during the study period; 43 (36.8%) of these had all of the
criteria for inclusion in the study. Clinical and demographic
data for the candidaemia and control groups are presented
in Table 1. The groups did not differ in terms of demog-
raphy, Simplified Acute Physiology Score and risk factors
for Candida infection, except for intestinal surgery, exclu-
sive parenteral nutrition and extrarenal epuration. A signifi-
cant difference in mortality was recorded during both the
ICU stay and the subsequent hospital stay.
The median delay between admission to the ICU and
appearance of candidaemia was 19 days (range: 10 to
31 days). Only one Candida species was found in BCs
(Candida albicans in 40.5%, Candida parapsilosis in
23.8%, Candida tropicalis in 19%, Candida glabrata in
16.7%), except for one patient who had both C. albicans
and C. parapsilosis. Weekly microbial surveillance of these
patients revealed that all were colonised by Candida spe-
cies. For the control patients, weekly multisite determin-
ation of yeast colonisation revealed that all except two
patients were colonised with Candida species and ap-
proximately one-third was colonised with more than one
species: two species in 15 patients, three species in eight
patients, and four species in two patients. The relativeprevalence of the different Candida species was similar to
that in the candidaemia group (in decreasing order:
C. albicans, C. parapsilosis, C. glabrata, C. tropicalis).
Glucanaemia and mannanaemia during the ICU stay
Glucanaemia and mannanaemia in sera from patients with
candidaemia are shown in Figure 1A and 1B, respectively, as
a function of weeks of hospitalisation before and after posi-
tive BCs. Glucanaemia was observed several weeks before
positive BC. The median delay between positive BDG and
Figure 1 Kinetics of β-D-1,3-glucan and mannan in candidaemic patients and controls. Levels of (A) β-D-1,3-glucan (BDG) and (B) mannan
were measured in 341 sera available from 43 patients with positive blood cultures. Sera were collected as a function of the number of weeks of
hospitalisation in the ICU, with D0 as the day on which the first positive blood culture was taken. Levels of (C) BDG and (D) mannan were
measured in 203 sera available from 67 control patients hospitalised on the same ward as a function of number of weeks of hospitalisation
(control group). cGLC, concentration of BDG; cMan, concentration of mannan.
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week before positive BC. At the date of positive BC, all sera/
patients had BDG levels >250 pg/ml. A global decrease in
BDG was then observed after week 3, although BDG per-
sisted in some patients for up to 8 weeks.
The data were analysed in terms of sensitivity, specificity
and likelihood ratios with reference to the kinetics of
BDG. The results are presented in Table 2 for the whole
period of serum collection. To respond to the questions
‘How can glycanaemia predict the onset of IC?’ and ‘How
can glycanaemia reveal IC?’ we considered the period
from day 7 before to day 7 after the first positive BC.
This analysis was also carried out for patients with
negative BCs.We then analysed how glycanaemia could predict re-
lapse or a favourable outcome by focusing on the 13 pa-
tients who had several episodes of candidaemia. Patients
were divided into two groups: those with the continuous
isolation of yeasts from blood with intervals of <48 hours
(two BCs for two patients, three BCs for four patients,
five BCs for one patient and nine BCs for one patient);
and patients with well-separated candidaemia episodes
corresponding to relapses (n = 5). The BDG and man-
nan Ab profiles of these patients are shown in Figure 2
and their clinical evolution is described in Additional
file 1. This panel of patients is representative of the di-
versity of conditions encountered in the ICU and sus-
ceptibility to IC.
Table 2 Sensitivity, specificity and likelihood ratios for glucanaemia and mannanaemia
Sensitivity Specificity Positive LR Negative LR
Week −8/+8 Day –7/+7 Week −8/+8 Day –7/+7 Week −8/+8 Day –7/+7 Week −8/+8 Day –7/+7
β-D-1,3-glucan 100 97.1 30.6 30.6 1.4 1.4 0 0.1
Mannan 38.5 32.3 95.8 95.8 9.2 7.7 0.6 0.7
Mannan antibody 58.1 52.9 66.2 66.2 1.7 1.6 0.6 0.7
Mannan or mannan antibody 79.5 58.8 66.2 64.8 2.4 1.7 0.3 0.6
Sensitivity, specificity and positive and negative likelihood ratios (LRs) for glucanaemia (β-D-1,3-glucan), mannanaemia and anti-mannan antibody detection tests,
as well as a combination of mannan/mannan antibody, during the whole period of serum collection (week 8 before to week 8 after the first positive blood culture
(Week −8/+8)), and the critical period for diagnosis (day 7 before to day 7 after the first positive blood culture (Day –7/+7)).
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mannan Ab in Figure 2, all patients (except Patient 4
with no detectable mannan) had values above the cutoff
point for all tests, but with different evolutions. There
were positive slopes for BDG and mannan before sec-
ondary candidaemia, but different kinetics of circulation
in a single patient. The well-known transient circulation
of mannan was observed and correlated with the inverse
evolution of mannan Ab (Patients 1, 2, 3 and 5). Inter-
estingly, a sharp decrease in BDG was observed in some
patients over a short period of time (see Patients 3, 4
and 5).
Besides the patients described above, the other 25 pa-
tients had no documented clinical or mycological signs
of relapse. The duration of the survey ranged from day 6
to day 102. At the end of the survey, 21 patients still had
BDG above the cutoff value and only four had BDG
below the cutoff value. When considering the evolution
of the BDG curve, a negative slope was observed for 10
patients, including two who were below the cutoff values
at day 9 and day 86, and two who became negative at day
71 and day 74; all other patients still had BDG >150 pg/
ml. Two patients had a positive slope close to BC isolation
(final points at 310 pg/ml and 760 pg/ml at day 6 and day
10, respectively). The other patients (n = 13) had stable
BDG levels above the cutoff value, including levels as
high as 2,223 pg/ml, 1,030 pg/ml and 1,458 pg/ml at day
7, day 12 and day 47, respectively. Median BDG and
median duration of the survey were 314 pg/ml and
18 days, respectively.Patients hospitalised in the ICU with no evidence of
Candida infection
The results of glucanaemia and mannanaemia tests for
the control group are shown in Figure 1C and 1D,
respectively, according to the duration of hospitalisation
(weeks). As early as the first week of hospitalisation,
about 50% of the patients presented at least one serum
sample with BDG above the cutoff value. This percent-
age remained stable during the following weeks, up to
more than 1 month of hospitalisation. By contrast, only
five (2%) sera samples taken from three different patientshad mannanaemia above the cutoff value, and this was
transient for all of them.
For the patients followed for Candida colonisation dur-
ing hospitalisation, glucanaemia was assessed as a function
of Candida load at the time of serum sampling. There
was no correlation between BDG and yeast load in these
patients and 17 (8.4%) sera samples had values over
1,000 pg/ml (Additional file 2). As shown in Additional
file 3, BDG was significantly associated with a high global
Candida load. Analysis of the effect of colonisation on
mannan did not show any correlation for the very limited
number (n = 3) of control patients with mannanaemia.
Impact of variation of the cutoff value on the
performance of β-D-1,3-glucan and mannan detection
Receiver operating characteristic curves for BDG and
mannan are shown in Figure 3 for the period from day 7
before to day 7 after the first positive BC. For BDG, for
a cutoff value of 1,600 pg/ml, sensitivity was 0.05 with a
specificity of >0.9. For a cutoff value of 800 pg/ml, the
respective values were 0.30 and 0.86. The best sensitivity/
specificity ratio (0.65/0.74) was obtained for a cutoff value
of 350 pg/ml. For mannan, the best sensitivity/specificity
ratio was 0.36/0.94 for a cutoff value of 0.2 ng/ml. From
these results it appears that these two tests could be use
to complement each other: mannan has an important
contribution to specificity for low BDG values, while high
BDG levels have improved sensitivity and specificity.
Discussion
In this study, we evaluated the diagnostic value of gluca-
naemia in combination with mannanaemia in sera taken
sequentially from ICU patients with candidaemia. In
parallel, we also assessed the effect of Candida colonisa-
tion on serum levels of Candida-derived polysaccharides
in patients from the same ICU department who did not
have candidaemia. Altogether, 543 sera taken from 110
patients were analysed. The method of inclusion was
intended to mimic clinical practice where clinicians have
to quickly identify any ICU patients needing antifungal
therapy, including those with negative BCs [6].
Glucanaemia was detected several days, or in some
cases weeks, before the isolation of Candida species
Figure 2 Kinetics of β-D-1,3-glucan, mannan and mannan antibody in five patients with candidaemia relapses. The dates of subsequent
Candida isolations from blood are indicated by arrows. All patients, except Patient 4 with no detectable mannan, had values above the cutoff
point for all tests, but with different kinetics. β-D-1,3-glucan (BDG) and mannan presented different kinetics of circulation in a single patient. The
well-known transient nature of circulating mannan was observed and correlated with an inverse evolution of mannan antibody (Patients 1, 2, 3
and 5). Interestingly a sharp decrease in BDG was also observed over a short period of time (Patients 3, 4 and 5). cGLC/cBDG, concentration of
BDG; cMn, concentration of mannan; Mn Ab, concentration of mannan antibody.
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measurement for the diagnosis of deep-seated mycoses
and fungal febrile episodes, Obayashi and colleaguesreported a sensitivity of 90% for a cutoff point of 20 pg/
ml [15]. However, subsequent studies gave disparate
results from different colorimetric and turbidimetric
Figure 3 Receiver operating characteristic curves for
β-D-1,3-glucan (plain line) and mannan (dotted line) for the
period from day 7 before to day 7 after the first positive blood
culture. Area under the curve (95% confidence interval) for β-D-1,
3-glucan (BDG) = 0.71 (0.61 to 0.81) with P < 0.0001; threshold for the
best sensitivity/specificity ratio, 353 (0.65 to 0.74). Area under the
curve (95% confidence interval) for mannan = 0.63 (0.52 to 0.74) with
P = 0.009; threshold for the best sensitivity/specificity ratio, 0.2 (0.36
to 0.94). When considering how the two tests could complement
each other, mannan has an important contribution to specificity for
low BDG values while higher BDG values have improved sensitivity
and specificity. cGLC, concentration of BDG; cMn, concentration
of mannan.
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of knowledge regarding the nature of the molecule(s)
detected [17]. With the Fungitell test, the multicentre
evaluation by Ostrosky-Zeichner and colleagues, includ-
ing 107 cases of proven candidosis, reported a sensitiv-
ity/specificity ratio of 0.60/0.92 for a cutoff point of
80 pg/ml, although their use of control sera from healthy
subjects could have led to an overestimation [18]. Using
hospitalised patients from a large hospital study as
controls, a similar sensitivity but lower specificity (70%)
was reported [19]; this decreased further in another
study involving surgical patients [13].
Impressive sensitivity and specificity (around 0.93) for
BDG detection for the diagnosis of candidaemia were re-
ported in septic patients with the early stages of fever
[20]. This contrasts with the lower performance of this
test reported in other studies [19,21], especially low
specificity [22]. Indeed, studies published to date report
a wide range of sensitivities and specificities for BDG de-
tection [23]. The impact of neutropaenia [24] on BDG
circulation is probably worth considering. However, in
our cohort, an analysis of sensitivity performed on data
collected from patients transferred from a haematology
ward suggested that the performance of BDG detection
was equivalent to that in non-neutropaenic patients
(data not shown). Altogether, the best sensitivity/specifi-
city ratio (0.65/074) for BDG was found for a cutoffvalue of 350 pg/ml, which is very close to that proposed
by Jaijakul and colleagues for predictive efficiency [25].
This study clearly shows that the decrease in BDG
over the course of the disease was much slower than the
decrease in mannan. The mechanism involved in the ca-
tabolism of β-glucans may involve antibodies participat-
ing in their clearance since the existence of human anti-
β-glucan antibodies has now been established [26,27], as
well as an increase in these antibodies during candidaemia
[28]. A second hypothesis for the difference in persistence
of BDG and mannan is serum mannosidases that cause
natural degradation/turnover of endogenous components;
this is not the case for glucans, which, like glucuronoxylo-
mannan of Cryptococcus neoformans, are resistant to
degradation and are purely exogenous in nature [29].
From a clinical point of view, the slow decrease in BDG
that we observed may limit its use for managing antifungal
treatment, a conclusion that contradicts a previous study
which proposed the follow-up of glucanaemia kinetics as a
tool to evaluate the efficacy of echinocandin therapy [25].
However, some patients with candidaemia enrolled in our
study had a second increase from their baseline BDG,
associated with high levels of mannan before secondary
BCs, suggesting that monitoring of glucanaemia and
mannanaemia in patients receiving antifungal therapy is a
useful strategy to identify patients with relapses.
The observation of persistently high BDG levels also
raises the question of their impact on modulation of the
immune response via their interaction with membrane
and soluble Pattern Recognition Receptors [30].
In the control group, quantitative snapshot analysis
did not reveal a correlation between BDG and yeast
burden. However, analysis of cumulative colonisation
revealed a trend for an association with BDG >1,000 pg/ml
(data shown in Additional file 1).
In contrast to BDG, only three control patients had
detectable mannan, in agreement with previous conclu-
sions that the detection of mannan with the Platelia test
has limited sensitivity but high specificity [11-13]. Here,
the unusually high frequency of candidaemia episodes
involving C. parapsilosis may also contribute to low sen-
sitivity observed. In contrast to the other more patho-
genic Candida species, the mannan epitope detected by
the Platelia test is poorly expressed on C. parapsilosis
[11]. As in a recent study [31], exclusion of C. parapsilo-
sis resulted in a moderate gain in sensitivity (from 38%
to 45%). Surprisingly, the specificity of BDG detection
was also affected by the exclusion of C. parapsilosis cases
(from 30% to 45%). This is of interest in view of the steady
increase in incidence of C. parapsilosis candidaemia [32].
The low sensitivity of mannan detection has been at-
tributed to the circulation of high levels of circulating
mannan Ab and soluble lectins such as mannan-binding
lectin forming immune complexes responsible for the
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led to the recommendation for repeated serum sampling
and combined mannan and mannan Ab screening to im-
prove the overall sensitivity of mannan-based diagnosis
[36]. This recommendation has never been reevaluated,
but it is interesting to observe here once again the relation
of the respective slopes where a sharp decrease in mannan
Ab is often predictive of a mannan peak and vice versa.
However, mannan gave the higher positive likelihood ratio
during the crucial period from day 7 before to day 7 after
the first positive BC (7.7 vs. 1.4 for BDG).
This study has several limitations, related to its retro-
spective character and possible selection bias linked to
the availability of sera from candidaemia patients and
the constitution of the control group. Nevertheless, this
latter group was representative of the high colonisation
levels encountered in ICU patients, as reported in stud-
ies involving surgical ICU patients [37] and medical ICU
patients who showed an increase in colonisation as a
function of the duration of hospitalisation and cumula-
tive exposure to risk factors [38]. This intense colonisa-
tion is itself a risk factor for the development of IC.
Indeed, application of Mohr and colleagues’ criteria [13]
led us to exclude a high proportion of patients from the
control cohort, defined as having possible or probable
IC. In our opinion, once this selection was made this
group represented appropriate controls for ICU daily
practice in order to evaluate the performance of bio-
markers at discriminating the transition from colonisa-
tion to infection, which concerns up to one patient in
10. The differences between the two populations re-
ported in Table 1 probably reflect both the background
and the impact of IC [37,38].Figure 4 Biomarker-based algorithm proposed for managing preemp
candidosis. IC, invasive candidosis.From this kinetic analysis, we propose an algorithm
(Figure 4) for preemptive treatment based on the principle
of biological screening of ICU populations, the majority
of whom are at high risk of IC. BDG detection is a more
sensitive, early positive test, and therefore appears use-
ful for first-line screening. For BDG values >800 pg/ml,
specificity values >90% require no confirmatory test.
For a cutoff value <800 pg/ml and >80 pg/ml, determin-
ation of mannan is indicated since the high correlation
between a combination of these two positive biomarkers
and IC could be an indication for preemptive treatment.
In other cases, regular monitoring of glucanaemia is
indicated since specificity increases by considering two
or more successive positive results [13,39] and the cost
of serological tests is minimal compared with antifun-
gal treatment administered at excess. The colonisation
index should be proposed as a last step despite its use-
fulness, due to the limitations of time constraints and
cost.
The retrospective application of this sequential prescrip-
tion of BDG and mannan detection in our cohort would
have led to the treatment of 24 patients on the basis of BDG
values >800 pg/ml and of five patients with BDG levels
between 80 and 800 pg/ml associated with positive manna-
naemia (total 29 patients = 70% of patients). When consider-
ing early positivity, more than 50% of the patients (22/41)
would have been treated before positive BCs. Among the
controls, 10 had positive BDG and four had positive man-
nan (14/67 = 15%). These results from the application of our
biomarker-based algorithm for preemptive antifungal the-
rapy compare favourably with empiric treatments, which
have been shown not to improve the outcome in cases of
fluconazole prescription [40] or to be cost-effective [41].tive therapy in ICU patients at high risk of developing invasive
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score-based therapy. Indeed, the clinical prediction rule de-
veloped by Ostrosky-Zeichner and colleagues captured
10.6% of the patients with proven/probable IC, but also
34.1% of patients without IC [42]; the Candida score
from Leon and colleagues exhibited an area under the
receiver operating characteristic curve of 0.774, a sensi-
tivity of 77.6 and a specificity of 66.2 [43]. A limitation
to this approach is that laboratory procedures often pre-
vent individual testing and, despite the fact that only 2
to 3 hours are needed to obtain the results, sera are
often treated as a series, once or twice a week. The peri-
odicity of testing should be adapted for institutions with
small numbers of samples or the tests should be
performed in a reference centre.
The data presented and discussed here suggest that,
due to the lack of sensitivity of BCs, managing thera-
peutic decisions using the Candida glycan detection test
is not unrealistic now that tests are able to detect mole-
cules in the range of picogrammes per millilitre with
high reliability. New more sensitive methods for the
detection of glycan biomarkers will probably be deve-
loped, establishing a panel of tests that cannot be
ignored for patient care, especially in the ICU.
Conclusion
An algorithm for preemptive therapy based on a combin-
ation of BDG and mannan detection was derived from a
kinetic analysis of a large volume of clinical and biological
data collected from patients hospitalised in the same ward
and who developed candidaemia or not. The follow-up of
BDG and mannan kinetics may also predict relapses. This
strategy, which could be adapted to the management of
the large number of ICU patients with negative
Candida BCs, should be validated through large
prospective studies.
Key messages
 Detection of Candida cell wall polysaccharides in
serum is a useful adjunct to BCs for the diagnosis
of IC in the ICU.
 The kinetics and duration of circulation differ
between BDG and mannan and between infected
patients and colonised controls: BDG is an early
sensitive biomarker but has low specificity, while
mannan appears later and is less sensitive, but has
high specificity.
 Increasing the cutoff value for BDG and combining
BDG detection with mannan detection can help in
preemptive therapy.
 Mannan and BDG follow-up is not useful for
monitoring treatment efficacy, but an increase in
these markers is predictive of relapse.Additional files
Additional file 1: is a clinical description of patients with relapses
of candidaemia, and for whom kinetics profiles of biomarkers are
shown in Figure 2.
Additional file 2: is a graphical representation of the distribution of
glucanaemia reported to the daily fungal load, showing there is no
correlation between colonisation and glucanaemia.
Additional file 3: is a graphical representation of the relation
between mean global Candida load and glucanaemia, showing a
trend for an association between a cumulative high level of
colonisation during all of the ICU stay and a high glucanaemia
level.
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